GLP-1 receptor agonists were tied to a 16% lower risk of epilepsy in adults with type 2 diabetes. Epilepsy is an ...

According to the analysis, people who used GLP-1 medications had a 16 percent lower risk of developing epilepsy than those who received DPP-4 inhibitors. The substance semaglutide stood out in ...

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published on December 10, 2025, in ...

According to a study published in Diabetes, Obesity and Metabolism, combining metformin with GLP-1 receptor agonists was ...

Dual therapy with metformin and GLP-1 RAs is associated with a lower risk for adiposity-related cancers and mortality than DPP-4 inhibitor therapy in patients with T2D.

With the skyrocketing popularity of GLP-1 RAs, some lesser-known side effects, including anemia, are coming to light.

A new study finds a possible association between GLP-1 drugs like semaglutide and chronic cough, though the authors are ...

For patients with type 2 diabetes, there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use ...

GLP-1 RAs show greater cardiovascular benefits in type 2 diabetes patients with BMI ≥25 compared to DPP-4 inhibitors. Kidney protection from GLP-1 RAs remains consistent across all BMI categories. The ...

USA: A new multicenter US cohort study has identified a potential link between the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) —widely prescribed for type 2 diabetes and obesity—and an ...

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk ...

A large US database study suggests GLP-1 receptor agonists may be associated with a reduced risk of developing epilepsy in ...